NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Premera Blue Cross, a regional health plan, has agreed to cover its ThyraMIR test for more than 2 million members located primarily in Washington, Oregon, and Alaska.

Premera Blue Cross has a network of more than 38,000 physicians, hospitals, laboratories, and other healthcare providers across the Northwest, Interpace said.

Its ThyraMIR assay is covered for thyroid nodules deemed indeterminate by standard cytopathological analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.